Engineered Oncolytic HSV for Local Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic therapies using viruses for cancer treatment face challenges such as variable tumor response and systemic off-target toxicity, particularly when combined with immune checkpoint blockade or co-stimulatory pathway activation, due to the lack of targeted immune response amplification and systemic effects.
Innovation Solution
An oncolytic herpes simplex virus (HSV) engineered to express GM-CSF and a molecule targeting an immune co-stimulatory pathway, such as CTLA-4 inhibitor, is used to selectively activate immune responses in tumors and tumor-draining lymph nodes, amplifying anti-tumor effects while minimizing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oncolytic viruses are combined with immune checkpoint blockade or co-stimulatory pathway activation, then anti-tumor immune responses are enhanced, but systemic off-target toxicity increases
Solution Approach 1:
The patent applies local quality by engineering the oncolytic virus to express immune modulatory molecules (GM-CSF and co-stimulatory pathway molecules) specifically within the tumor microenvironment. This localized expression enhances anti-tumor immune responses at the tumor site while minimizing systemic exposure and off-target toxicity. The virus delivers these molecules directly to tumor cells and the surrounding microenvironment, creating a focused therapeutic effect.
Solution Approach 2:
The oncolytic virus serves as an intermediary delivery vehicle that transports immune modulatory molecules (GM-CSF and co-stimulatory pathway molecules) specifically to the tumor site. This viral mediator enables targeted immune response amplification without requiring systemic administration of these molecules, thereby reducing off-target effects while maintaining therapeutic efficacy.
2Reliability
If oncolytic viruses express multiple immune modulatory molecules, then immune response amplification is enhanced, but device complexity increases
Solution Approach 1:
The patent merges multiple immune modulatory functions into a single oncolytic virus platform. The virus simultaneously expresses GM-CSF (a cytokine that activates antigen-presenting cells) and co-stimulatory pathway molecules (such as CD40L, OX40L, or 4-1BBL) to amplify anti-tumor immune responses. This combination approach consolidates multiple therapeutic mechanisms into one delivery system, enhancing immune activation while streamlining the overall treatment architecture.
Solution Approach 2:
The engineered oncolytic virus exhibits multi-functionality by performing several therapeutic roles simultaneously: (1) direct oncolytic activity to kill tumor cells, (2) expression of GM-CSF to activate antigen-presenting cells, and (3) expression of co-stimulatory pathway molecules to enhance T-cell activation and proliferation. This universal platform addresses multiple aspects of anti-tumor immunity through a single therapeutic agent.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.